Is NVCR or DCTH more profitable?

Delcath Systems has a net margin of 0.62% compared to NovoCure's net margin of -25.66%. Delcath Systems' return on equity of 0.51% beat NovoCure's return on equity. Company Net Margins Return on Equity Return on Assets NovoCure -25.66% -50.82% -16.48% Delcath Systems 0.62% 0.51% 0.46%

Is DCTH or ENOV more profitable?

Delcath Systems has a net margin of 0.62% compared to Enovis' net margin of -49.92%. Enovis' return on equity of 10.32% beat Delcath Systems' return on equity. Company Net Margins Return on Equity Return on Assets Delcath Systems 0.62% 0.51% 0.46% Enovis -49.92% 10.32% 4.57%

Delcath Systems (DCTH) Competitors

$12.94 0.00 (0.00%)

Closing price 06/26/2026 04:00 PM Eastern

Extended Trading

$13.38 +0.44 (+3.40%)

As of 04:47 AM Eastern

Compare

DCTH vs. NVCR, EYE, ENOV, BLFS, and KMTS

Should you buy Delcath Systems stock or one of its competitors? MarketBeat compares Delcath Systems with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Delcath Systems include NovoCure (NVCR), National Vision (EYE), Enovis (ENOV), BioLife Solutions (BLFS), and Kestra Medical Technologies (KMTS). These companies are all part of the "medical equipment" industry.

How does Delcath Systems compare to NovoCure?

NovoCure (NASDAQ:NVCR) and Delcath Systems (NASDAQ:DCTH) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, analyst recommendations, institutional ownership, dividends, valuation and profitability.

Delcath Systems has a net margin of 0.62% compared to NovoCure's net margin of -25.66%. Delcath Systems' return on equity of 0.51% beat NovoCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NovoCure	-25.66%	-50.82%	-16.48%
Delcath Systems	0.62%	0.51%	0.46%

In the previous week, NovoCure had 3 more articles in the media than Delcath Systems. MarketBeat recorded 4 mentions for NovoCure and 1 mentions for Delcath Systems. Delcath Systems' average media sentiment score of 1.87 beat NovoCure's score of 0.97 indicating that Delcath Systems is being referred to more favorably in the news media.

Company	Overall Sentiment
NovoCure	Positive
Delcath Systems	Very Positive

Delcath Systems has lower revenue, but higher earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NovoCure	$655.35M	2.73	-$136.23M	-$1.53	N/A
Delcath Systems	$85.23M	5.24	$2.70M	$0.01	1,294.00

NovoCure currently has a consensus price target of $25.67, suggesting a potential upside of 66.34%. Delcath Systems has a consensus price target of $22.50, suggesting a potential upside of 73.88%. Given Delcath Systems' stronger consensus rating and higher possible upside, analysts plainly believe Delcath Systems is more favorable than NovoCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NovoCure	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
Delcath Systems	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43

NovoCure has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market. Comparatively, Delcath Systems has a beta of 0.54, indicating that its stock price is 46% less volatile than the broader market.

84.6% of NovoCure shares are held by institutional investors. Comparatively, 61.1% of Delcath Systems shares are held by institutional investors. 5.5% of NovoCure shares are held by company insiders. Comparatively, 19.4% of Delcath Systems shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Delcath Systems beats NovoCure on 12 of the 16 factors compared between the two stocks.

How does Delcath Systems compare to National Vision?

National Vision (NASDAQ:EYE) and Delcath Systems (NASDAQ:DCTH) are both small-cap medical equipment companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, media sentiment, institutional ownership and valuation.

National Vision has a net margin of 2.31% compared to Delcath Systems' net margin of 0.62%. National Vision's return on equity of 6.41% beat Delcath Systems' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
National Vision	2.31%	6.41%	2.81%
Delcath Systems	0.62%	0.51%	0.46%

In the previous week, National Vision had 1 more articles in the media than Delcath Systems. MarketBeat recorded 2 mentions for National Vision and 1 mentions for Delcath Systems. Delcath Systems' average media sentiment score of 1.87 beat National Vision's score of 0.82 indicating that Delcath Systems is being referred to more favorably in the news media.

Company	Overall Sentiment
National Vision	Positive
Delcath Systems	Very Positive

National Vision has higher revenue and earnings than Delcath Systems. National Vision is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
National Vision	$1.99B	0.76	$29.60M	$0.57	33.09
Delcath Systems	$85.23M	5.24	$2.70M	$0.01	1,294.00

61.1% of Delcath Systems shares are owned by institutional investors. 2.4% of National Vision shares are owned by insiders. Comparatively, 19.4% of Delcath Systems shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

National Vision has a beta of 1.08, meaning that its share price is 8% more volatile than the broader market. Comparatively, Delcath Systems has a beta of 0.54, meaning that its share price is 46% less volatile than the broader market.

National Vision presently has a consensus price target of $30.08, indicating a potential upside of 59.51%. Delcath Systems has a consensus price target of $22.50, indicating a potential upside of 73.88%. Given Delcath Systems' higher probable upside, analysts plainly believe Delcath Systems is more favorable than National Vision.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
National Vision	0 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.58
Delcath Systems	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43

Summary

National Vision beats Delcath Systems on 10 of the 16 factors compared between the two stocks.

How does Delcath Systems compare to Enovis?

Delcath Systems (NASDAQ:DCTH) and Enovis (NYSE:ENOV) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, media sentiment, valuation, risk and analyst recommendations.

Delcath Systems presently has a consensus target price of $22.50, indicating a potential upside of 73.88%. Enovis has a consensus target price of $44.50, indicating a potential upside of 97.40%. Given Enovis' stronger consensus rating and higher possible upside, analysts plainly believe Enovis is more favorable than Delcath Systems.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Delcath Systems	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43
Enovis	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

61.1% of Delcath Systems shares are owned by institutional investors. Comparatively, 98.5% of Enovis shares are owned by institutional investors. 19.4% of Delcath Systems shares are owned by company insiders. Comparatively, 2.9% of Enovis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Delcath Systems has a beta of 0.54, suggesting that its stock price is 46% less volatile than the broader market. Comparatively, Enovis has a beta of 1.38, suggesting that its stock price is 38% more volatile than the broader market.

Delcath Systems has a net margin of 0.62% compared to Enovis' net margin of -49.92%. Enovis' return on equity of 10.32% beat Delcath Systems' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Delcath Systems	0.62%	0.51%	0.46%
Enovis	-49.92%	10.32%	4.57%

In the previous week, Enovis had 2 more articles in the media than Delcath Systems. MarketBeat recorded 3 mentions for Enovis and 1 mentions for Delcath Systems. Delcath Systems' average media sentiment score of 1.87 beat Enovis' score of 0.56 indicating that Delcath Systems is being referred to more favorably in the media.

Company	Overall Sentiment
Delcath Systems	Very Positive
Enovis	Positive

Delcath Systems has higher earnings, but lower revenue than Enovis. Enovis is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Delcath Systems	$85.23M	5.24	$2.70M	$0.01	1,294.00
Enovis	$2.25B	0.58	-$1.18B	-$19.88	N/A

Summary

Enovis beats Delcath Systems on 9 of the 16 factors compared between the two stocks.

How does Delcath Systems compare to BioLife Solutions?

BioLife Solutions (NASDAQ:BLFS) and Delcath Systems (NASDAQ:DCTH) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, media sentiment, analyst recommendations, dividends and profitability.

93.2% of BioLife Solutions shares are held by institutional investors. Comparatively, 61.1% of Delcath Systems shares are held by institutional investors. 2.2% of BioLife Solutions shares are held by company insiders. Comparatively, 19.4% of Delcath Systems shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

BioLife Solutions has a beta of 2, meaning that its stock price is 100% more volatile than the broader market. Comparatively, Delcath Systems has a beta of 0.54, meaning that its stock price is 46% less volatile than the broader market.

In the previous week, BioLife Solutions had 1 more articles in the media than Delcath Systems. MarketBeat recorded 2 mentions for BioLife Solutions and 1 mentions for Delcath Systems. Delcath Systems' average media sentiment score of 1.87 beat BioLife Solutions' score of 1.17 indicating that Delcath Systems is being referred to more favorably in the news media.

Company	Overall Sentiment
BioLife Solutions	Positive
Delcath Systems	Very Positive

Delcath Systems has a net margin of 0.62% compared to BioLife Solutions' net margin of -2.80%. BioLife Solutions' return on equity of 1.81% beat Delcath Systems' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioLife Solutions	-2.80%	1.81%	1.65%
Delcath Systems	0.62%	0.51%	0.46%

Delcath Systems has lower revenue, but higher earnings than BioLife Solutions. BioLife Solutions is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLife Solutions	$96.21M	14.55	-$4.59M	-$0.08	N/A
Delcath Systems	$85.23M	5.24	$2.70M	$0.01	1,294.00

BioLife Solutions presently has a consensus target price of $32.00, suggesting a potential upside of 11.67%. Delcath Systems has a consensus target price of $22.50, suggesting a potential upside of 73.88%. Given Delcath Systems' stronger consensus rating and higher possible upside, analysts clearly believe Delcath Systems is more favorable than BioLife Solutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLife Solutions	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Delcath Systems	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43

Summary

Delcath Systems beats BioLife Solutions on 9 of the 16 factors compared between the two stocks.

How does Delcath Systems compare to Kestra Medical Technologies?

Kestra Medical Technologies (NASDAQ:KMTS) and Delcath Systems (NASDAQ:DCTH) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, earnings, risk, dividends, media sentiment, valuation, analyst recommendations and profitability.

Kestra Medical Technologies currently has a consensus target price of $27.40, indicating a potential upside of 3.67%. Delcath Systems has a consensus target price of $22.50, indicating a potential upside of 73.88%. Given Delcath Systems' stronger consensus rating and higher possible upside, analysts clearly believe Delcath Systems is more favorable than Kestra Medical Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kestra Medical Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Delcath Systems	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43

Delcath Systems has higher revenue and earnings than Kestra Medical Technologies. Kestra Medical Technologies is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kestra Medical Technologies	$59.81M	25.79	-$113.81M	-$3.96	N/A
Delcath Systems	$85.23M	5.24	$2.70M	$0.01	1,294.00

61.1% of Delcath Systems shares are held by institutional investors. 3.6% of Kestra Medical Technologies shares are held by insiders. Comparatively, 19.4% of Delcath Systems shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Kestra Medical Technologies had 4 more articles in the media than Delcath Systems. MarketBeat recorded 5 mentions for Kestra Medical Technologies and 1 mentions for Delcath Systems. Delcath Systems' average media sentiment score of 1.87 beat Kestra Medical Technologies' score of 0.37 indicating that Delcath Systems is being referred to more favorably in the news media.

Company	Overall Sentiment
Kestra Medical Technologies	Neutral
Delcath Systems	Very Positive

Kestra Medical Technologies has a beta of 0.83, suggesting that its stock price is 17% less volatile than the broader market. Comparatively, Delcath Systems has a beta of 0.54, suggesting that its stock price is 46% less volatile than the broader market.

Delcath Systems has a net margin of 0.62% compared to Kestra Medical Technologies' net margin of -171.87%. Delcath Systems' return on equity of 0.51% beat Kestra Medical Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kestra Medical Technologies	-171.87%	-65.49%	-46.39%
Delcath Systems	0.62%	0.51%	0.46%

Summary

Delcath Systems beats Kestra Medical Technologies on 13 of the 16 factors compared between the two stocks.

Get Delcath Systems News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DCTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DCTH vs. The Competition

Export

Metric	Delcath Systems	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$446.69M	$7.36B	$6.83B	$12.17B
Dividend Yield	N/A	1.24%	2.66%	6.11%
P/E Ratio	1,294.00	51.24	25.89	24.17
Price / Sales	5.24	48.77	546.41	101.77
Price / Cash	247.54	26.99	29.09	36.93
Price / Book	4.11	7.53	10.79	6.38
Net Income	$2.70M	$159.19M	$3.58B	$337.00M
7 Day Performance	12.42%	2.61%	1.97%	-0.20%
1 Month Performance	20.04%	-2.37%	-0.24%	-1.40%
1 Year Performance	-4.64%	5.96%	34.40%	27.76%

Delcath Systems Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DCTH Delcath Systems	2.5351 of 5 stars	$12.94 flat	$22.50 +73.9%	-4.6%	$446.69M	$85.23M	1,294.00	60	Positive News Gap Down High Trading Volume
NVCR NovoCure	3.1809 of 5 stars	$14.15 +4.0%	$26.86 +89.8%	-14.3%	$1.64B	$674.41M	N/A	1,605	Gap Down
EYE National Vision	3.7887 of 5 stars	$17.32 +2.1%	$30.08 +73.7%	-18.6%	$1.39B	$2.02B	30.38	13,138	Positive News
ENOV Enovis	4.166 of 5 stars	$21.38 +0.4%	$44.50 +108.1%	-29.1%	$1.23B	$2.25B	N/A	7,802	Positive News Analyst Downgrade
BLFS BioLife Solutions	3.0595 of 5 stars	$25.17 +1.1%	$32.00 +27.1%	+33.3%	$1.23B	$96.21M	N/A	440	Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DCTH) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Delcath Systems (DCTH) Competitors

DCTH vs. NVCR, EYE, ENOV, BLFS, and KMTS

How does Delcath Systems compare to NovoCure?

Summary

How does Delcath Systems compare to National Vision?

Summary

How does Delcath Systems compare to Enovis?

Summary

How does Delcath Systems compare to BioLife Solutions?

Summary

How does Delcath Systems compare to Kestra Medical Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DCTH vs. The Competition

Delcath Systems Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Delcath Systems (DCTH) Competitors

DCTH vs. NVCR, EYE, ENOV, BLFS, and KMTS

How does Delcath Systems compare to NovoCure?

Is NVCR or DCTH more profitable?

Does the media refer more to NVCR or DCTH?

Which has higher earnings and valuation, NVCR or DCTH?

Do analysts prefer NVCR or DCTH?

Which has more risk & volatility, NVCR or DCTH?

Do insiders & institutionals hold more shares of NVCR or DCTH?

Summary

How does Delcath Systems compare to National Vision?

Is EYE or DCTH more profitable?

Does the media favor EYE or DCTH?

Which has preferable earnings & valuation, EYE or DCTH?

Do institutionals & insiders have more ownership in EYE or DCTH?

Which has more risk & volatility, EYE or DCTH?

Do analysts prefer EYE or DCTH?

Summary

How does Delcath Systems compare to Enovis?

Do analysts prefer DCTH or ENOV?

Do institutionals and insiders believe in DCTH or ENOV?

Which has more volatility & risk, DCTH or ENOV?

Is DCTH or ENOV more profitable?

Does the media refer more to DCTH or ENOV?

Which has higher earnings & valuation, DCTH or ENOV?

Summary

How does Delcath Systems compare to BioLife Solutions?

Do institutionals & insiders believe in BLFS or DCTH?

Which has more volatility and risk, BLFS or DCTH?

Does the media favor BLFS or DCTH?

Is BLFS or DCTH more profitable?

Which has better valuation & earnings, BLFS or DCTH?

Do analysts rate BLFS or DCTH?

Summary

How does Delcath Systems compare to Kestra Medical Technologies?

Do analysts rate KMTS or DCTH?

Which has higher valuation & earnings, KMTS or DCTH?

Do insiders & institutionals have more ownership in KMTS or DCTH?

Does the media prefer KMTS or DCTH?

Which has more volatility and risk, KMTS or DCTH?

Is KMTS or DCTH more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DCTH vs. The Competition

Delcath Systems Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools